Who gets to be an “expert” on Covid-19? Are Americans entitled to drugs that don’t work? And how does the FDA deal with states’ rights?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the FDA’s decision to halt the use of two Covid-19 antibodies that don’t work against Omicron — and the surprising backlash that ensued. Then, acting FDA commissioner Janet Woodcock joins us to dig into the agency’s move and discuss the steps for regulation of Covid drugs. We also go over the latest news in the life sciences, including some bad news for Gilead Sciences and a rare victory for a small biotech company.
How continuous glucose monitors are transforming diabetes care
Continuous glucose monitoring, or CGM, is transforming diabetes care. Where a diagnosis once meant a lifetime of finger pricking and injections, these devices now help achieve less invasive monitoring and treatment for the millions of Americans living with diabetes. With prescriptions of CGMs increasing, the question remains – can these devices become the standard of care? Our latest report looks to answer this question, analyzing our best intelligence on the burgeoning industry of CGM, and examining where the industry is likely to head next.
No comments